2023-503170-20-01招募中1 期
A Phase I Study of RO7589831 Alone and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 46
- 试验地点
- 8
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Rajesh Belani, MD
Scientific
Vividion Therapeutics Inc.
研究点 (8)
Loading locations...
相似试验
招募中
1 期
First-in-Human Study of RO78126532025-522101-37-00F. Hoffmann-La Roche AG12
招募中
1 期
A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants with Type 2 Diabetes Mellitus(T2DM) and Overweight or Obesity2025-521401-41-00F. Hoffmann-La Roche AG30
招募中
1 期
A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.2024-511110-21-00F. Hoffmann-La Roche AG140
已完成
1 期
A phase Ib study to investigate the safety and effect of BR-0032024-516338-37-00SentryX B.V.6
招募中
1 期
A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-targeting CAR-T cells in patients with relapsed and refractory B-cell malignancies (CARLOTTA01)2022-502831-20-00Technische Universitat Dresden16